Table 3 HPV-specific risks for LCT results
From: HPV-specific risk assessment of cervical cytological abnormalities
Genotypes | LCT (−) | LCT (+) | P | OR (for LCT (+)) | 95%CI |
|---|---|---|---|---|---|
HPV-16 | 74 (4.2%) | 73 (15.2%) | < 0.001 | 4.06 | 2.89–5.71 |
HPV-18 | 28 (1.6%) | 20 (4.2%) | 0.001 | 2.672 | 1.49–4.79 |
HPV-31 | 14 (0.8%) | 11 (2.3%) | 0.009 | 2.906 | 1.31–6.44 |
HPV-33 | 23 (1.3%) | 21 (4.4%) | < 0.001 | 3.433 | 1.88–6.26 |
HPV-35 | 2 (0.1%) | 3 (0.6%) | 0.062 | 5.493 | 0.92–32.97 |
HPV-39 | 24 (1.4%) | 20 (4.2%) | < 0.001 | 3.125 | 1.71–5.71 |
HPV-45 | 1 (0.1%) | 5 (1.0%) | 0.008 | 18.397 | 2.14–157.84 |
HPV-51 | 9 (0.5%) | 12 (2.5%) | < 0.001 | 4.956 | 2.08–11.83 |
HPV-52 | 85 (4.9%) | 80 (16.7%) | < 0.001 | 3.916 | 2.83–5.42 |
HPV-53 | 34 (1.9%) | 34 (7.1%) | < 0.001 | 3.845 | 2.36–6.26 |
HPV-56 | 7 (0.4%) | 14 (2.9%) | < 0.001 | 7.475 | 3.00–18.63 |
HPV-58 | 50 (2.9%) | 55 (11.5%) | < 0.001 | 4.397 | 2.96–6.54 |
HPV-59 | 7 (0.4%) | 12 (2.5%) | < 0.001 | 6.38 | 2.50–16.30 |
HPV-66 | 10 (0.6%) | 17 (3.5%) | < 0.001 | 6.384 | 2.90–14.04 |
HPV-68 | 21 (1.2%) | 17 (3.5%) | 0.001 | 3.021 | 1.58–5.77 |
HPV-6 | 11 (0.6%) | 9 (1.9%) | 0.015 | 3.019 | 1.24–7.33 |
HPV-11 | 12 (0.7%) | 13 (2.7%) | 0.001 | 4.029 | 1.83–8.89 |
HPV-42 | 1 (0.1%) | 3 (0.6%) | 0.038 | 10.992 | 1.14–105.91 |
HPV-43 | 2 (0.1%) | 1 (0.2%) | 0.624 | 1.823 | 0.17–20.15 |
HPV-44 | 8 (0.5%) | 4 (0.8%) | 0.326 | 1.828 | 0.55–6.10 |
cp8304 | 28 (1.6%) | 26 (5.4%) | < 0.001 | 3.52 | 2.04–6.06 |
multiple HPV infection | 72 (4.1%) | 100 (20.9%) | < 0.001 | 6.131 | 4.439–8.467 |